Thalassaemia trials in China

In China 28 Also abroad 73

28 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
Where
Tianjin
Age
3 years to 14 years
People
100
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05991336
No phaseNot yet taking people in China
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
Where
Shenzhen
Age
4 years to 70 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03351829
Phase 1/2Taking people
β-Thalassemia Treatment With KL003 Cell Injection
Where
Shanghai, Tianjin
Age
3 years to 35 years
People
41
Run by
Kanglin Biotechnology (Hangzhou) Co., Ltd.
See details and how to joinNCT06280378
No phaseTaking people
A Long-term Follow-up Study in Participants Who Received CS-101
Where
Shanghai
Age
3 years to 17 years
People
5
Run by
Children's Hospital of Fudan University
See details and how to joinNCT06479616
No phaseTaking people
Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children
Where
Haikou
Age
3 years to 17 years
People
30
Run by
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07725263
No phaseTaking people
Long-term Follow-up Study of BRL-101 for TDT
Where
Changsha, Guangxi, Guangzhou, Nanning, Shenzhen, Tianjin
Age
3 years to 35 years
People
45
Run by
Bioray Laboratories
See details and how to joinNCT06298630
Phase 2Taking people
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Where
Chengdu, Guangzhou, Nanning, Shenzhen
Age
6 years to 17 years
People
99 worldwide
Run by
Celgene
See details and how to joinNCT04143724 · EU 2022-502499-22-00
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Tianjin
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Early phase 1Enrolling by invitation
CS-101 in Patients With β-thalassemia
Where
Nanning
Age
6 years to 35 years
People
10
Run by
CorrectSequence Therapeutics Co., Ltd
See details and how to joinNCT06328764
Phase 2Not yet taking people in China
A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)
Where
Chengdu, Foshan, Guangzhou, Haikou, Liuzhou, Maoming, Nanning
Age
18 years and over
People
30
Run by
ScinnoHub Pharmaceutical Co., Ltd.
See details and how to joinNCT07579949
Phase 2Not yet taking people in China
A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
Where
Nanning, Shanghai
Age
12 years to 35 years
People
20
Run by
CorrectSequence Therapeutics Co., Ltd
See details and how to joinNCT07489196
Phase 2Taking people
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Where
Guangzhou, Haikou, Liuzhou, Maoming, Nanning
Age
18 years to 65 years
People
64
Run by
Kind Pharmaceuticals LLC
See details and how to joinNCT06302491
No phaseEnrolling by invitation
A Long-term Follow-up Study in Participants Who Received CS-101
Where
Nanning
Age
6 years to 35 years
People
5
Run by
CorrectSequence Therapeutics Co., Ltd
See details and how to joinNCT06685536
No phaseEnrolling by invitation
A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
Where
Nanning
Age
12 years to 35 years
People
8
Run by
CorrectSequence Therapeutics Co., Ltd
See details and how to joinNCT06717932
Phase 2Taking people
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Where
Baise City, Kunming, Liuzhou, Naning, Shenzhen, Yulin
Age
18 years to 75 years
People
78
Run by
Rongrong Liu
See details and how to joinNCT07338344
Early phase 1Not yet taking people in China
YOLT-204 in Patients With Hemoglobinopathies
Where
Guangzhou
Age
3 years to 17 years
People
18
Run by
Guangzhou Women and Children's Medical Center
See details and how to joinNCT07190001
No phaseTaking people
A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
Where
Kunming
Age
7 years to 12 years
People
5
Run by
Hu Peng
See details and how to joinNCT06743477
Phase 1Taking people
A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
Where
Haikou, Nanning
Age
18 years to 65 years
People
40
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT06772766
No phaseTaking people
Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
Where
Guangzhou
Age
7 years to 10 years
People
3
Run by
Guangzhou Women and Children's Medical Center
See details and how to joinNCT06734520
Early phase 1Taking people
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
Where
Shenzhen
Age
8 years to 16 years
People
10
Run by
Shenzhen Hemogen
See details and how to joinNCT05745532
Early phase 1Taking people
the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
Where
Nanning
Age
12 years to 35 years
People
3
Run by
Shenzhen Hemogen
See details and how to joinNCT05851105
Early phase 1Taking people
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
Where
Shenzhen
Age
18 years to 35 years
People
3
Run by
Shenzhen Hemogen
See details and how to joinNCT05864170
Phase 2Taking people
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Where
Haikou, Liuzhou, Maoming, Nanning, Yulin
Age
3 years to 20 years
People
396
Run by
Rongrong Liu
See details and how to joinNCT06657391
Phase 1Taking people
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
Where
Guangxi, Shenzhen
Age
6 years to 35 years
People
8
Run by
Shenzhen Hemogen
See details and how to joinNCT06655662
Phase 1Taking people
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
Where
Guangzhou, Nanning, Shanghai
Age
3 years to 35 years
People
9
Run by
Shanghai BDgene Co., Ltd.
See details and how to joinNCT06465550